NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that full results from the Phase 2 clinical trial for the assessment ...

The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offisite pharmacy and delivered as a ready-to-use unit dose. The Food and Drug Administration (FDA) ...

-- Company’s Novel Imaging Agents in Development for Evaluation of Coronary Artery Disease and Heart Failure to be Featured in 14 Presentations -- “The amount of data on two of our PET cardiac imaging ...

Please provide your email address to receive an email when new articles are posted on . Despite these findings, a question persists over whether good decisions can be made regarding benefit in ...

Photo Credit: Adapted from de Winter RW, et al. EuroIntervention. 2021;Epub ahead of print. Used with permission. Remote myocardial perfusion increases after revascularization of a chronic total ...

Patients who receive cardiac positron emission testing (PET) imaging instead of single photon emission computed tomography (SPECT) scan experienced a significant increase in the detection of severe ...

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), American Society of Nuclear Cardiology (ASNC), European Association of Nuclear Medicine (EANM), and American College of Nuclear Medicine ...

A positron emission tomography (PET) scan is a diagnostic tool that examines body tissue functioning, such as blood flow, oxygen use, and sugar metabolism, to help doctors diagnose and treat disease.

The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offsite pharmacy and delivered as a ready-to-use unit dose. The approval was supported by data from ...